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Abstract: Farnesyltransferase inhibitors (FTIs) represent a new class of signal transduction 
inhibitors that block the processing of cellular polypeptides that have cysteine terminal residues 
and, by so doing, interdict multiple pathways involved in proliferation and survival of diverse 
malignant cell types. Tipifarnib is an orally bioavailable, nonpeptidomimetic methylquinolone 
FTI that has exhibited clinical activity in patients with myeloid malignancies including elderly 
adults with acute myelogenous leukemia (AML) who are not candidates for traditional cytotoxic 
chemotherapy, patients with high-risk myelodysplasia, myeloproliferative disorders, and imatinib-
resistant chronic myelogenous leukemia. Because of its relatively low toxicity proﬁ  le, tipifarnib 
provides an important alternative to traditional cytotoxic approaches for elderly patients who 
are not likely to tolerate or even beneﬁ  t from aggressive chemotherapy. In this review, we will 
focus on the clinical development of tipifarnib for treatment of newly diagnosed AML, both as 
induction therapy for elderly adults with poor-risk AML and as maintenance therapy following 
achievement of ﬁ  rst complete remission following induction and consolidation therapies for 
poor-risk AML. As with all other malignancies, the optimal approach is likely to lie in rational 
combinations of tipifarnib with cytotoxic, biologic and/or immunomodulatory agents with 
non-cross-resistant mechanisms of action. Gene expression proﬁ  ling has identiﬁ  ed networks of 
differentially expressed genes and gene combinations capable of predicting response to single 
agent tipifarnib. The clinical and correlative laboratory trials in progress and under development 
will provide the critical foundations for deﬁ  ning the optimal roles of tipifarnib and in patients 
with AMl and other hematologic malignancies.
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Cure rates for adults with acute myelogenous leukemia (AML) remain inadequate. 
Poor-risk features such as age   60, secondary AML including prior myelodysplasia 
(MDS) and treatment-related AML (t-AML), adverse cytogenetics, and hyperleukocy-
tosis with extramedullary disease in the absence of “favorable” cytogenetics identify 
patients who are not only less likely to achieve remissions with cytotoxic chemotherapy 
but who are predisposed to shorter disease free survival despite intensive induction 
and post-remission therapies (Lancet et al 2000; Grimwade et al 2001; Goldstone et al 
2001; Appelbaum et al 2006; Estey 2007).
In particular, the response rates and survival for adults age 70 and older with 
AML remain limited. Part of this poor response relates to the inability of very 
elderly patients (age   75) to tolerate intensive chemotherapy (Lancet et al 2000; 
Appelbaum et al 2006; Estey 2007). Equally important, however, is the genetic 
complexity and inherent resistance of these AMLs to the cytotoxic effects of 
traditional cytotoxic agents (Grimwade et al 2001; Goldstone et al 2001; Appelbaum 
et al 2006). AMLs that arise in the older age group often do so from an antecedent 
hematologic disorder, mainly MDS which itself has evolved from a background of Biologics: Targets & Therapy 2008:2(3) 492
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toxin exposures (Grimwade et al 2001; Appelbaum et al 
2006; Estey 2007). These MDS/AMLs exhibit a complex 
genetic profile, likely a result of cumulative genomic 
damage (Grimwade et al 2001).
Farnesyltransferase inhibitors (FTIs) are small molecule 
signal transduction inhibitors that inhibit critical cell growth 
and survival pathways (reviewed by Karp and Lancet 2007). 
These agents are potent and selective competitive inhibitors 
of farnesyltransferase (FTase), an intracellular enzyme that 
catalyzes the transfer of the 15-carbon farnesyl moiety to a 
cysteine close to the C-terminus of a substrate polypeptide 
(End 1999; Basso et al 2006). A host of intracellular poly-
peptides including the small GTP-binding polypeptides of 
the Ras, Rho-B and Rheb families, membrane lamins, and 
centromeric proteins (CENPs) that interact with microtubules 
to promote the completion of mitosis, are substrates for pre-
nylation via FTase (reviewed by Reuter et al 2000; Sebti and 
Der 2003; Karp and Lancet 2007). Inhibiting farnesylation 
of these polypeptides leads to diminished cell proliferation 
and, in some model systems, cell death. These cytotoxic 
effects have been attributed to FTI-induced inhibition of 
prosurvival signaling by Akt (Jiang et al 2000), the Rheb 
target mTOR (Castro et al 2003; Sebti and Adjei 2004; Witzig 
and Kaufmann 2006), or mitogen activated protein (MAP) 
kinases (reviewed by Reuter et al 2000; Morgan and Reuter 
2006). Alternatively, it has been suggested that FTIs induce 
apoptosis by causing upregulation of the proapoptotic Bcl-2 
family members Bax (Beaupre et al 2004), Bak (Feldkamp 
et al 1999), or PUMA (Gomez-Benito et al 2005).
While FTIs were initially developed on the premise 
that FT inhibition would prevent the post- translational 
processing of Ras proteins and thereby impede an early 
junctional process in overall signal transduction (reviewed 
by End 1999; Basso et al 2006), it is not surprising that their 
activity is not necessarily limited to ras mutated tumors nor 
is the effect equal among tumors bearing different mutated 
ras isoforms. Indeed, FTIs are by no means “selective” as 
they target proteins involved in disparate pathways and 
thereby exert their cytotoxic effects by interdicting multiple 
mechanisms of cellular survival, including angiogenesis, 
cellular adhesion, and inhibition of apoptosis. This notion 
is further substantiated by DNA microarray analyses of 
selected AML cell lines and primary AML marrow blasts, 
where tipifarnib modulates the expression of several gene 
networks, upregulating multiple genes involved in apoptosis, 
immunity, cell-cell adhesion and cytoskeletal organization, 
while downregulating genes involved in proliferation and 
cell cycle progression (Raponi et al 2004).
Hematologic malignancies provide a fertile testing ground 
for such agents because of the relative ease with which 
tumor tissue can be obtained throughout the therapeutic 
course. The ability to obtain target tissue in a longitudinal 
fashion provides a unique opportunity to deﬁ  ne the relevant 
molecular components that may be modulated by these com-
pounds and to relate those molecular effects to the clinical 
outcome. At present, three non-peptidomimetic FTIs are 
being tested clinically in a broad spectrum of hematologic 
malignancies: tipifarnib (R115777, Zarnestra), lonafarnib 
(SCH66336), and BMS-214662. To date, all three exhibit 
clinical and molecular biologic activities in diverse myeloid 
malignancies and MM with modest and acceptable toxicities. 
In particular, tipifarnib has exhibited clinical activity in 
patients with myeloid malignancies including elderly adults 
with AML who are not candidates for traditional cytotoxic 
chemotherapy (Karp et al 2001; Lancet et al 2007), patients 
with high-risk MDS (Kurzrock et al 2003, 2004; Fenaux et al 
2007), myeloproliferative disorders (Mesa et al 2007), and 
imatinib-resistant chronic myelogenous leukemia (Cortes 
et al 2003). In this review, we will focus on the clinical devel-
opment of tipifarnib for treatment of newly diagnosed AML, 
both as induction therapy for elderly adults with poor-risk 
AML and as maintenance therapy after achievement of ﬁ  rst 
complete remission (CR) after induction and consolidation 
therapies for poor-risk AML.
Clinical trials of tipifarnib 
as induction therapy
Single-agent studies (Table 1)
The ﬁ  rst clinical testing of FTIs in AML was a Phase I 
trial of the orally bioavailable FTI Tipifarnib administered 
for 21 days in patients with relapsed or refractory AML 
(Karp et al 2001). Consistent inhibition of FTase activity 
occurred at or above 300 mg bid orally and dose-limiting 
toxicity (DLT), manifested as readily reversible central 
neurotoxicity, was observed at 1200 mg bid. Oral absorp-
tion was rapid, with linear pharmacokinetics, and there was 
a dose-dependent increase in drug concentration in marrow 
with sustained levels 2- to 3-fold higher than concomitant 
levels in peripheral blood. Clinical responses were observed 
in 10 of 34 patients (29%), including 2 complete remissions 
(CRs) in patients with relapsed AML, and occurred across all 
dosing levels (100–900 mg bid) without strict relationship 
to the degree of leukemic cell FTase inhibition. Intrigu-
ingly, responses were independent of ras mutational status, 
as none of the 34 leukemic samples demonstrated an N-ras 
mutation (Karp et al 2001). Expansion of these ﬁ  ndings in Biologics: Targets & Therapy 2008:2(3) 493
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an international Phase II study (Harousseau 2007a) yielded a 
CR rate of only 4% but, importantly, provided a template for 
subsequent studies of gene expression proﬁ  ling to uncover 
determinants of response to tipifarnib (Raponi 2007).
Based on the Phase I ﬁ  ndings (Karp 2001), Lancet et al 
(2007) conducted a unique Phase II study of tipifarnib admin-
istered at a dose of 600 mg bid for 21 out of 28–63 days for 
158 older adults with previously untreated, poor-risk AML. 
The median age was 74, 75% had antecedent MDS, and 
47% had adverse cytogenetics. Treatment-related mortality 
was 7%. The CR rate in these elderly, poor-risk patients 
was 14% with an additional 10% partial response (partial 
remission, PR; hematologic improvement, HI). Among 
patients achieving CR, 82% had prior MDS and 40% had 
adverse cytogenetics. While median overall survival (OS) for 
all 158 patients was 5.3 months, median CR duration was 
7.3 months and median OS for CR patients was 18.3 months. 
Patients who achieved PR or HI enjoyed a survival advan-
tage as well, with a median OS 12.6 months. In contrast, 
median survival for patients who did not evince any type of 
response was 3.6 months. The lack of correlation between 
ras mutational status and clinical response was conﬁ  rmed 
(Raponi et al 2008). Measurements of inhibition of farne-
sylation of the chaperone protein HDJ-2 in marrow blasts 
obtained on day 8 of tipifarnib therapy revealed an increase 
in unfarnesylated protein in 75% of marrow samples, while 
inhibition of farnesylation of the nuclear membrane protein 
Lamin A could be detected in 92% of all concomitantly-
obtained samplers of buccal mucosa (Lancet et al 2007). 
This provocative ﬁ  nding may provide insight into potential 
mechanisms of FTI resistance, as discussed later in this 
review.
A randomized Phase III study of tipifarnib 600 mg bid 
for 21 out of 28 days vs best supportive care (including 
hydroxyurea) of 457 adults over age 70 with newly diag-
nosed, poor risk AML who were not ﬁ  t for conventional 
chemotherapy was recently completed in Europe and Canada 
(Harousseau et al 2007). Durable CR (median DFS 8 months, 
median OS 22 months) was achieved in 8% of those random-
ized to tipifarnib, while there were no CRs in the supportive 
care/hydroxyurea arm. Disappointingly, however, there was 
no statistically signiﬁ  cant OS beneﬁ  t with tipifarnib treatment 
and the trial was deemed negative.
Explorations of alternative doses and schedules of 
tipifarnib are underway. The North American Intergroup 
conducted a Phase II 4-arm study of different doses (300 mg 
bid vs 600 mg bid) and schedules (daily × 21 days vs one 
week-on, one week-off) of single-agent tipifarnib as induction 
Table 1 Trials of single agent tipifarnib in acute myelogenous leukemia
Phase Patient population Tipifarniba 
dose-schedule
Response rate Author
I Rel/Refa 100–1200, 21/28 days CR 8% (2/34) Karp (2001)
MTD 900 OR 29% (10/34)
I Rel/Ref 400–1400, alternate week CR 33% (3/9) Kirschbaum (2007)
MTD 1200 @ MTD
II Rel/Ref 600, 21/28 days CR 7% (11/169) Harousseau (2007a)
sCR 4% (6/169)
med OS 12.2 mo
II New Dx 600, 21/28–63 days CR 14% (22/158) Lancet (2007)
Poor risk OR 23% (37/158)
Age   65 med DFS 7.3 mo
CR med OS 18.6 mo
II New Dx 300–600, 21/28 days CR 6–15% Erba (2007)
Age   70 vs alternate week CR 15%/OR 20%
@ 300 × 21/28 days
III New Dx 600 mg, 21/28 days CR 8% (18/228) Harousseau (2007b)
Poor risk vs BSC including HU med DFS 8 mo
Age   70 (vs 0% BSC/HU arm) CR med OS 20 mob
amg bid.
bno signiﬁ  cant difference between tipifarnib and BSC arms with regard to OS.
Abbreviations: Rel/Ref, relapsed/refractory; CR, complete remission; sCR, sustained complete remission; OR, overall response; MTD, maximal tolerated dose; DFS, disease-
free survival; OS, overall survival; BSC, best supportive care; HU, hydroxyurea; mo, months.Biologics: Targets & Therapy 2008:2(3) 494
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therapy for adults over age 70 with newly diagnosed AML 
(Erba et al 2007). While CRs and PRs were seen in all arms 
with acceptable toxicity proﬁ  les, the most salutary outcome 
was deﬁ  ned for those patients receiving tipifarnib 300 mg 
bid for 21 days, with a 20% overall response rate (15% CR, 
5% PR) and a 1-year survival of roughly 30%. Molecular 
analyses aimed at predicting response are planned. In a similar 
vein, a Phase I dose-escalation trial of a 1-week-on, 1-week-off 
schedule in adults with relapsed and refractory AML has 
deﬁ  ned the maximal tolerated dose (MTD) as 1200 mg bid, 
with the DLT being renal toxicity, and achievement of CR in 
3 of 9 treated at or near the MTD (Kirschbaum et al 2007).
Combinatorial approaches (Table 2)
While FTIs demonstrate reproducible activities as single 
agents, the resultant outcomes are modest. In order to 
improve the robustness of these results, the full development 
of FTIs in the therapeutic armamentarium for hematologic 
(and other) malignancies will require the design and testing 
of rational combinations of FTIs with cytotoxic, biologic 
and immunomodulatory agents in both the laboratory and 
the clinic. This is a burgeoning area of investigation in both 
the clinical and the laboratory arenas.
The combination of tipifarnib with conventional ara-C and 
anthracycline-based chemotherapy is under study by multiple 
investigators in newly diagnosed AML patients. In a Phase 
I–II study in 95 patients ages 15–70 (median age 50) with 
newly diagnosed AML or high-risk MDS, the MD Anderson 
group (Delmonte et al 2007) added tipifarnib 300 mg bid 
to idarubicin plus ara-C (IA) induction and consolidation 
followed by 6 months of cyclical tipifarnib maintenance 
therapy. The addition of tipifarnib to IA induction yielded 
a 73% CR/CRp rate (64% CR, 9% CRp), which is iden-
tical to the group’s data with IA alone in a historically 
similar population. With the addition of tipifarnib, CRs were 
achieved in 69% with adverse cytogenetics (13/19 of patients 
with −5/−7, 21/35 with other abnormalities) and 12/16 (75%) 
with FLT-3 mutations. Major grade 3 toxicities included 
reversible diarrhea, rash and hyperbilirubinemia, induction 
mortality was very low. Median CR duration with tipifarnib 
is 17 months (12 month CR duration with IA alone) and the 
median OS is roughly the same as with similar historical 
controls (70 weeks vs 65 weeks, respectively). Additional 
observation and direct comparison between IA and IA plus 
tipifarnib in a prospective randomized Phase III trial will 
be needed to determine if the outcome with tipifarnib is 
superior to IA alone.
In a similar vein, a group led by investigators at Princess 
Margaret Hospital in Toronto, Ontario, Canada have con-
ducted a Phase I dose-escalation study of tipifarnib added to 
conventional ara-C plus daunorubicin on days 6–15 of induc-
tion and consolidation therapies for newly diagnosed adults 
age 60 and older (Brandwein et al 2007), with achievement 
of CR in 9/22 (41%) and 2 PR, for an overall response rate 
of 50%. Of 7 with adverse cytogenetics 3 (43%) achieved 
CR and 1 achieved PR. Tipifarnib dose escalation up to 
600 mg bid was well tolerated, albeit with mildly increased 
gastrointestinal toxicity, and a Phase II study with tipﬁ  arnib 
at 600 mg bid days 6–15 plus ara-C and daunorubicin is under 
development for adults  60 years.
While it is possible that the antileukemic effects of 
tipifarnib might be enhanced by adjustment of the dose or 
Table 2 Trials of tipifarnib in combination with chemotherapeutic agents
Phase Patient population
(Author)
Dose-schedules Response rate
Tipifarniba Chemotherapy
I New Dx  300, 400, 600 etoposide CR 25% (21/84)
Poor risk  14 vs 21 days 100, 150, 200 mg med DFS 9.8 mo
Age   70  Days 1–3 and 8–10 CR med OS 22 mo
(Karp 2006)
I New Dx  200–600  ara-C 100 mg/m2day CI × 7 CR 41% (9/22)
Age   60 Days 6–15 daunorubicin 60 mg/m2/day × 3 OR 50% (11/22)
(Brandwein 2007)
II New Dx  300 ara-C 1.5 g/m2/day CI × 3–4 CR 69% (70/95)
Age 17–61 idarubicin 12 mg/m2/day med DFS 17 mo
(Delmonte 2007)
amg bid.
Abbreviations: CR, complete remission; CRp, complete remission with incomplete platelet recovery; DFS, disease-free survival; OR, overall response; OS, overall 
survival; mo, months.Biologics: Targets & Therapy 2008:2(3) 495
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schedule, an alternative approach would be to combine this 
agent with existing antileukemic therapy. Toward this end, 
preclinical studies have revealed that the antiproliferative 
effects in human AML cells in vitro are additive when tipi-
farnib is combined with cladrabine or ﬂ  udarabine (Korycka 
et al 2004) and synergistic when tipifarnib is combined 
with bortezomib (Yanamandra et al 2006) or daunorubicin 
(Medeiros et al 2007). Interestingly, tipifarnib appears to 
inhibit the drug efﬂ  ux activity of the prototypical drug resis-
tance protein P-glycoprotein (P-gp) in a dose-dependent 
fashion in human acute T-lymphoblastic leukemia and AML 
cell lines in a manner that is independent of its FT inhibitory 
activity (Medeiros 2007). This P-gp inhibition may be a part of 
the synergistic interaction between tipifarnib and daunorubicin 
and, at least in theory, could apply to combinations of tipifarnib 
with other P-gp substrates such as etoposide (Mahadevan and 
List 2004; Medeiros et al 2007). Moreover, the ability of tipi-
farnib to modulate P-gp activity and the possibility that such 
modulation could contribute to synergy with antileukemic 
agents such as daunorubicin and etoposide may have special 
relevance to elderly patients with AML, where high levels of 
P-gp expression are common and correlate with clinical drug 
resistance (Leith et al 1999; Appelbaum et al 2006).
The topoisomerase II poison etoposide, which stabilizes 
covalent adducts between the nuclear enzyme topoisomerase II 
and DNA (Li and Liu 2001; Wang 2002), has been used 
alone and in combination for acute leukemias and has 
demonstrated efﬁ  cacy, particularly when combined with 
other cytotoxic agents (Evans and Prentice 1982; Bishop 
et al 1990; Bolanos-Meade et al 2003). Etoposide exhibits 
limited activity as a single agent when given intravenously in 
doses of 200–400 mg/m2 daily × 5 and orally at daily doses 
of 200–500 mg × 5–7 days (Evans and Prentice 1982). Oral 
etoposide at doses of 75–125 mg/m2 (100–200 mg) daily × 
3–5 has been combined with oral idarubicin at doses of 
20–30 mg/m2 daily × 3–5 as induction therapy for small 
numbers of selected AML patients  55 years (Jackson
et al 1997; Oriol et al 2003; Fiegl et al 2005), with CR 
rates ranging from 0% to 30% but with short CR dura-
tions (Jackson et al 1997; Fiegl et al 2005) and signiﬁ  cant 
treatment-related toxicity and death (Oriol et al 2003; Fiegl 
et al 2005).
A multicenter Phase I trial of oral tipifarnib plus oral 
etoposide (T + E) was designed with escalating doses of 
both drugs and exploration of two different durations of 
tipifarnib administration (14 vs 21 days) to examine the 
safety and tolerability of T + E in patients  70 years 
who were not candidates for conventional induction 
chemotherapy and to preliminarily assess the antileukemic 
activity of the combination (Karp et al 2006). A total of 
84 patients (median age 77) received 224 cycles of tipifarnib 
(300–600 mg bid for 14 or 21 days) + etoposide (100–200 mg 
daily on days 1–3 and 8–10). All patients had at least 1 
poor-risk feature in addition to age, including secondary 
AML (55%), adverse cytogenetics (54%), and/or 3 or more 
non-hematologic co-morbidities (45%). In the previous 
phase II study of single-agent tipifarnib administered at 
600 mg bid for 21 consecutive days, grade 3 or 4 adverse 
events occurred in 47% of in elderly AML patients (Lancet 
et al 2007). When the same 21-day schedule of tipifarnib 
was combined with etoposide, grade 4 oral mucositis, grade 
3 hyperbilirubinemia, and multi-organ failure were detected 
at tipifarnib doses of 400 mg twice daily, independent of 
etoposide dose. In contrast, the same etoposide schedule 
was much better tolerated when tipifarnib was administered 
for 14 days without any dose limiting toxicities, even at a 
tipifarnib dose of 600 mg bid. Oral mucositis, a well-known 
toxicity of etoposide, has not accompanied previous studies 
of single-agent tipifarnib (Karp et al 2001; Kurzrock et al 
2004; Fenaux et al 2007; Lancet et al 2007) The apparent 
relationship between tipifarnib schedule and mucositis 
induction may represent synergy between tipifarnib and 
etoposide against normal oral mucosa. On the other hand, 
tipifarnib-related neurotoxicity was not enhanced by 
combination with etoposide.
For the entire group of 84 patients, the CR rate was 25%, 
with median CR duration being 9.8 months (range 3–31 
months) and median OS being 22 months (range 3.5–36+), 
with 67% surviving for more than 1 year and 43% alive at 
16+ to 36+ months. When the relationship between dose 
or schedule and response was examined, CR was achieved 
in 31% of the patients receiving tipifarnib doses of at least 
400 mg twice daily and in 16/54 (30%) patients receiving 
14-day T vs 5/30 (17%) receiving 21-day. Interestingly, 
CR rates of 50% (3/6 patients per cohort) were achieved 
in three of the 14-day cohorts where tipifarnib dose was at 
least 400 mg twice daily in combination with etoposide at 
100 or 200 mg daily. Thus, this combination has yielded 
encouraging clinical results, with a CR rate that is almost 
double that achieved with tipifarnib alone (Lancet et al 
2007) in a group of patients for whom traditional antileu-
kemia chemotherapy may not be appropriate because of 
advanced age, poor risk biologic disease features, and/or 
the presence of signiﬁ  cant non-hematologic co-morbidities 
(Appelbaum et al 2006; Estey 2007). In view of the results 
observed, a randomized multicenter Phase II trial is planned Biologics: Targets & Therapy 2008:2(3) 496
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to compare two 14-day cohorts to select the optimal doses 
of  T+E that will produce the maximal CR rate with the most 
acceptable toxicity proﬁ  le.
Treatment of minimal residual 
disease: maintenance therapy
Maintenance chemotherapy in CR after multiple cytotoxic 
regimens is effective in the setting of acute lymphoblastic 
leukemia but has not yet proven to lengthen CR in AML, 
particularly in older patients or those with poor-risk features 
(Cassileth et al 1992; Lowenberg et al 1998; Goldstone 
et al 2001; Buchner et al 2006; Estey 2007). Nonetheless, 
the concept of maintenance therapy after intensive therapy 
is appealing if indeed such therapy could prolong CR or 
prevent relapse without incurring serious toxicities or 
clonal evolution of remaining leukemic cells. It is becoming 
increasingly possible to identify AML patients whose 
CR durations are predicted to be short, based on clinical 
and biologic features that reﬂ  ect inherent drug resistance 
(Harris et al 1999; Grimwade et al 2001; Arber et al 2003; 
Bullinger et al 2004; Yanada et al 2005; Radmacher et al 
2006; Estey et al 2007; Mrozek et al 2007). Indeed, in adults 
with one or more poor-risk features, the median CR duration 
is  9 months and the 1-year DFS is 20% (Archimbaud et al 
1999; Goldstone et al 2001; Stone et al 2001; Bolanos-Meade 
et al 2003; Breems et al 2005; Estey 2007). In such patients, 
the so-called “minimal residual disease” (MRD) state should 
provide a fertile testing ground for new approaches aimed at 
prolonging CR and preventing or deterring relapse.
In this regard, it is reasonable to speculate that FTIs 
might suppress regrowth of the malignant clone when the 
residual tumor burden after cytotoxic chemotherapies has 
been reduced to a minimal state. This concept has now been 
tested in patients with AML with poor-risk features in ﬁ  rst 
CR who are expected to relapse in less than 1 year (age   60 
and/or secondary AML or adverse cytogenetics) (Karp et al 
2008). In a Phase II trial of tipifarnib monotherapy for 48 
such adults with poor-risk AML in ﬁ  rst CR, tipifarnib 400 mg 
bid for 14 out of 21 days was initiated after recovery from 
consolidation chemotherapy, for a maximum 16 cycles. 
Twenty (42%) completed 16 cycles, 24 (50%) were removed 
from study for relapse, and 4 (8%) discontinued drug pre-
maturely for intolerance. Non-hematologic toxicities were 
rare, but tipifarnib dose was reduced in 58% for myelosup-
pression. Median DFS was 13.5 months (range 3.5–60+), 
with 30% having DFS   2 years. When CR durations for 
patients who received tipifarnib maintenance were compared 
with the CR durations of historically similar patients who 
received the same induction and consolidation therapies but 
did not receive tipifarnib, DFS for patients with secondary 
AML (p = 0.01), adverse cytogenetics (p = 0.07), or both 
poor-risk features (p = 0.02) appeared to be prolonged with 
tipifarnib. This effect of tipifarnib for patients with secondary 
AML and/or adverse cytogenetics is consistent with previous 
demonstrations of tipifarnib activity in patients with high-
risk MDS (Fenaux et al 2007) and in elderly patients with 
MDS/AML including those with adverse cytogenetics (Karp 
et al 2006; Lancet et al 2007). On the other hand, historical 
comparison suggested that tipifarnib maintenance may not 
prolong DFS in patients whose sole risk factor was age   60 
and whose AML did not exhibit poor risk biology. A random-
ized trial, as is currently underway in the Eastern Cooperative 
Oncology Group (ECOG), will be needed to demonstrate any 
deﬁ  nitive beneﬁ  t of tipifarnib as post-remission maintenance 
therapy for any subgroups of patients with AML with poor-
risk features, in particular those with secondary AML and/or 
adverse cytogenetics.
One future goal is to determine who will beneﬁ  t from 
the addition of tipifarnib in the MRD setting. This may be 
particularly challenging in patients with normal cytogenetics, 
where clinical outcomes and cure rates can vary dramatically, 
reﬂ  ecting heterogeneity on the molecular level (Bullinger 
et al 2004; Wilson et al 2006; Mrozek et al 2007). In this 
regard, recent studies have deﬁ  ned single gene mutations 
and gene expression signatures that may help to discrimi-
nate prognostic subgroups in cytogenetically “normal” 
AML (Radmacher et al 2006; Mrozek et al 2007). In sum, 
the results of this limited Phase II study suggest that some 
patients with poor-risk AML, including those with secondary 
AML and/or adverse cytogenetics, may beneﬁ  t from tipifarnib 
maintenance therapy without incurring clinically or biologi-
cally signiﬁ  cant risks. Future studies of this approach should 
examine alternative tipifarnib dosing (eg, reduced dosing, 
different schedules) and continuation of therapy beyond 
16 cycles, as well as a randomized, placebo-controlled trial 
of tipifarnib maintenance therapy. Finally, stratiﬁ  cation 
based on molecular features may reﬁ  ne the ability to target 
the subset of patients who stand to derive the greatest beneﬁ  t 
from the tipifarnib maintenance approach.
Resistance to tipifarnib
Malignant cells have an uncanny ability to become resis-
tant to new antitumor agents, and it is likely that the FTIs 
will be no exceptions. Such resistance, whether intrinsic or 
acquired, limits net drug efﬁ  cacy. To date, resistance to FTIs 
has been demonstrated in diverse cell lines that have been Biologics: Targets & Therapy 2008:2(3) 497
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developed via selective adaptation (Prendergast et al 1996; 
Smith et al 2002; Bruzek et al 2005; Buzzeo et al 2005; 
Zhang et al 2005) or have been genetically engineered to 
express FT enzyme mutations (Del Villar et al 1999; Raz et al 
2007). For example, a tipifarnib-resistant human colon cancer 
cell line, generated by continuous drug exposure, exhibits a 
marked reduction in the FT enzyme itself without enzyme 
mutations or aberrations in activation of enzyme subunits 
(Prendergast et al 1996). In a similar construct, a lonafarnib-
resistant Ph+ALL cell line from transgenic mice has been 
generated by growing those cells on stroma in the presence of 
increasing lonafarnib concentrations (Zhang et al 2005). The 
resultant lonafarnib-resistant cells exhibit marked increase 
in gene expression of the novel ATP binding cassette (ABC) 
transporter homolog ATP11a and are, interestingly, relatively 
resistant to imatinib as well. A novel MM line derived from 
8226 (8226/R5) exhibits resistance to both tipifarnib and 
bortezomib, with such resistance unrelated to FTase muta-
tions, drug transporters, or heat shock protein expression 
(Buzzeo et al 2005). In comparison with drug sensitive 8226 
cells, gene expression proﬁ  ling of the resistant 8226/R5 cells 
revealed increased expression of Jak2 and Stat1 with marked 
elevation in both phosphorylated Stat1 and Stat3 and, as a 
result of activated Stat3, an increase in BCL-XL mRNA and 
protein expression. In addition, 8226/R5 cells were found to 
overexpress a particular isoform of the PI3K p110 subunit. 
It is reasonable to speculate that overexpression of key 
components of the PI3/AKT anti-apoptosis pathway by any 
mechanism might be expected to confer relative resistance 
to FTI-induced apoptosis. Indeed, this appears to be the case 
in the generation of resistance to lonafarnib in the HCT116 
human colon cancer cell line, which appears to relate to an 
increase in Akt and/or its downstream intermediaries (Bruzek 
et al 2005). Whether or not any of these mechanisms of resis-
tance are clinically relevant is not yet known. The elucidation 
of these and other mechanisms of resistance at both cellular 
and humoral levels of drug disposition is an important aspect 
of the ongoing clinical development of FTIs.
In the clinical arena, Goemans et al (2005) examined drug 
sensitivity proﬁ  les of pediatric leukemias, using a methyl-
thiazole-tetrazolium (MTT) assay to compare tipifarnib 
responsiveness with traditional cytotoxic agents. T-cell ALLs 
and acute monoblastic AMLs exhibited the greatest tipifarnib 
sensitivity without correlation between ras mutational status 
or in vitro drug responsiveness but with correlation in AML 
samples between resistance to tipifarnib and resistance to 
anthracyclines or etoposide. These studies may be a useful 
template for understanding shared mechanisms of drug 
resistance among structurally diverse compounds and, in 
turn, providing insights into strategies by which to overcome 
such resistance factors.
Gene expression: insights 
into FTI mechanisms of action 
and prediction of response
The ability to identify molecular predictors of response to 
speciﬁ  c drugs or drug combinations should direct the selec-
tion of a therapeutic approach that is most likely to induce 
meaningful clinical response. Toward this end, microarray 
technology provides a spectrum of gene expression signatures 
in AML which, in turn, affords a molecular stratiﬁ  cation of 
patients with respect to disease biology and clinical outcome. 
Raponi et al (2004) have conducted serial studies of gene 
expression proﬁ  ling in the context of AML cell lines and 
primary AML marrow cells exposed to tipifarnib in vitro, 
in marrow blasts from patients with relapsed and refractory 
AML undergoing treatment with tipifarnib alone (Harousseau 
et al 2007a; Raponi et al 2007), and most recently in marrow 
blasts from elderly adults with previously untreated AML 
with poor-risk features who received tipifarnib alone as 
induction therapy (Lancet et al 2007; Raponi et al 2008). 
Each of these studies has identiﬁ  ed networks of differentially 
expressed genes and gene combinations capable of predicting 
response to single agent tipifarnib. The in vitro studies identi-
ﬁ  ed integrated gene networks whose activities are modulated 
in an orchestrated fashion to yield net cell death in diverse 
AML cell lines and in primary AML marrow samples, while 
the studies in AML cells from patients with relapsed and 
refractory AML identiﬁ  ed a signature of 8 genes that are 
differentially expressed in responders vs nonresponders, 
with overexpression of one gene in particular, the lymphoid 
blast crisis oncogene (oncoLBC or AKAP13), capable of 
accurately predicting clinical response to tipifarnib (Raponi 
et al 2007). Provocatively, the AKAP13 protein acts as a 
guanine nucleotide exchange factor for Rho proteins (Zheng 
et al 1995; Toksoz et al 2004) and contains a region that is 
homologous to an α-helical domain known to interact with 
nuclear envelope protein lamin B (Foisner et al 1991). This 
is especially intriguing because Rho and lamin proteins are 
farnesylated, and AKAP13 activates both types of proteins. 
The recent discovery that lamin B is critical to the assembly 
of the mitotic spindle (Tsai et al 2006) makes it tempting 
to speculate that AKAP13 might have an indirect role in 
promoting or permitting completion of mitosis, perhaps in 
concert with another group of FTI targets, namely CENPs. 
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from elderly adults with newly diagnosed, poor-risk AML 
(Raponi et al 2008) demonstrate that response to tipifarnib 
relates to the expression of two speciﬁ  c genes: up-regulation 
of the gene encoding the guanine nucleotide exchange factor 
RASGRP1, which activates Ras, and down-regulation of 
APTX, the gene encoding the DNA excision repair protein 
aprataxin (Ahel et al 2006). Conversely, active aprataxin 
may be able to repair damaged DNA in a way that uncouples 
the detection of that damage and the eventual completion of 
programmed cell death. It should be noted that the studies 
to date have been conducted in relatively small numbers of 
patients and may therefore be somewhat biased. Nonethe-
less, the continuing efforts to compare gene expression 
proﬁ  les of AML marrow blasts obtained pretreatment and 
during treatment with tipifarnib alone or in combination with 
other agents hold promise for identifying genomic markers 
that could accurately predict susceptibility vs resistance to 
tipifarnib-based therapies.
Perspectives for continuing clinical 
development of tipifarnib
In summary, tipifarnib inhibits malignant cell growth and 
survival by interfering with multiple intracellular signaling 
pathways. As a single agent, it has reproducible clinical 
effects on AML and other hematologic malignancies, but 
to date those effects are detected in a minority of patient 
subgroups. There are a number of potential explanations 
for the less-than-robust clinical results with FTIs as single 
agents, including inherent patient and disease heterogeneity, 
potential recruitment of survival pathways including 
DNA repair, and activation of other post-translational 
processing enzymes (eg, geranylgeranyltransferase) that 
might circumvent the effects of FT inhibition. As with all 
other malignancies, the optimal approach is likely to lie 
in rational combinations of tipifarnib or other FTIs with 
cytotoxic, biologic, and/or immunomodulatory agents with 
non-cross-resistant mechanisms of action. The clinical trials 
currently in progress will provide the critical foundations 
for deﬁ  ning the optimal roles of tipifarnib in patients with 
diverse hematologic malignancies.
The precise mechanisms by which tipifarnib exerts its 
cytotoxicity remain to be deﬁ  ned. The original notion that 
these agents targeted Ras mutations is clearly not complete, 
and it is likely that all FTIs have an impact on multiple 
molecules and pathways involved in cellular integrity. 
Studies to deﬁ  ne the mechanisms by which tipifarnib alters 
cellular metabolism and modulate the activities of speciﬁ  c 
signaling pathways in normal and malignant precursors 
are a pivotal part of this effort. In this regard, the potential 
impact of FTIs on other disease processes is presaged by 
the ability of ABT-100 to ameliorate the process of pre-
mature aging in a mouse model of progeria which, like 
the human condition, is characterized by accumulation of 
an abnormally farnesylated form of the lamin A precursor 
prelamin A, disruption of orderly nuclear scaffolding, and 
resultant misshapen nuclei (Fong et al 2006). The clinical 
and correlative laboratory trials in progress and under devel-
opment will provide the critical foundations for deﬁ  ning the 
optimal roles of tipifarnib and other FTIs in patients with 
cancer, and perhaps other diseases of disordered cellular 
metabolism as well.
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